Encompass Health Corp
Encompass Health (EHC) reported Q2 2026 net operating revenue of $1.597B (+9.6% YoY), adjusted EBITDA of $348M (+9.2%), and adjusted EPS of $1.55 (+10.7%). Full-year 2026 guidance was raised: revenue $6.41B-$6.49B, adjusted EBITDA $1.365B-$1.395B, adjusted EPS $6.02-$6.25. The company also increased its $1B share repurchase authorization.
COLTHARP DOUGLAS E (EVP & Chief Financial Officer) sold 18,869 shares of Encompass Health Corp (EHC) at $125.38 ($2.37M total) on 2026-08-10.
Tarr Mark J (President & CEO) sold 173,148 shares of Encompass Health Corp (EHC) at an average of $125.47 ($125.46–$126.06, $21.72M total) across 2 trades on 2026-08-10.
Over the past 7 days, alphai's AI scored 7 news stories mentioning EHC (Encompass Health Corp). Coverage has skewed bullish: 5 bullish, 2 neutral, and 0 bearish.
Recent EHC coverage spans earnings, insider activity and corporate actions.
In the last 30 days, EHC insiders filed 4 SEC Form 4 transactions — no purchases and 4 sales ($25.2M). The most active reporter was Tarr Mark J, President & CEO, with 2 filings.
Guidance raise plus higher occupancy and discharge growth supports a bullish re-rating, while Medicare Advantage denial risk remains a key swing factor.
This is an insider sale disclosure, not a fundamental company update, but it can modestly affect near-term sentiment.
This is a large insider sale by the CEO, which can modestly pressure sentiment, but it is not a fundamental change by itself.
The filing is a routine insider sale with no stated 10b5-1 plan, but it does not by itself signal a fundamental change.
Guidance raise and a fresh $1B buyback program support a bullish near-term bias, but the article frames it as analyst reiteration rather than a new catalyst today.
alphai scores every news story that mentions EHC with an AI model for sentiment and relevance, and aggregates insider trades from Encompass Health Corp's SEC EDGAR Form 4 filings. Figures refresh continuously.
Encompass Health (EHC) reported Q2 2026 net operating revenue of $1.597B (+9.6% YoY), adjusted EBITDA of $348M (+9.2%), and adjusted EPS of $1.55 (+10.7%). Full-year 2026 guidance was raised: revenue $6.41B-$6.49B, adjusted EBITDA $1.365B-$1.395B, adjusted EPS $6.02-$6.25. The company also increased its $1B share repurchase authorization.
6 min readCOLTHARP DOUGLAS E (EVP & Chief Financial Officer) sold 18,869 shares of Encompass Health Corp (EHC) at $125.38 ($2.37M total) on 2026-08-10.
1 min readTarr Mark J (President & CEO) sold 173,148 shares of Encompass Health Corp (EHC) at an average of $125.47 ($125.46–$126.06, $21.72M total) across 2 trades on 2026-08-10.
2 min readDarby John Patrick (EVP, Gen Counsel & Secretary) sold 8,906 shares of Encompass Health Corp (EHC) at $125.95 ($1.12M total) on 2026-08-10.
1 min readTD Cowen analyst Ryan Langston reiterated Encompass Health (EHC) as a top small- and mid-cap pick after its strong Q2 FY2026 results. Adjusted EBITDA was $348M (+3% vs consensus), revenue $1.597B (+10%), and EPS $1.55. Same-store volume rose 2.8%. EHC raised FY2026 adjusted EBITDA guidance by $15M and authorized a $1B share repurchase.
2 min readEncompass Health (EHC) reported Q2 results and raised 2026 guidance. Q2 revenue rose 9.6% to support adjusted EBITDA of $348 million (+9.2%) and adjusted EPS up 10.7%. Full-year 2026 net operating revenue is guided to $6.41B-$6.49B, adjusted EBITDA $1.365B-$1.395B, and adjusted EPS $6.02-$6.25.
6 min readEncompass Health Corp. (NYSE: EHC) priced a private offering of $100 million additional 5.875% senior notes due 2034 at 98.75% of principal, reopening its May 2026 issue. Interest begins Dec. 1, 2026. Proceeds plus cash will repay amounts under its senior secured revolving credit facility. Expected close Aug. 13, 2026.
3 min readMizuho updated its U.S. healthcare “Top Picks” list for 2026, citing seven companies across biotech, medical devices, and healthcare services. Highlights include Eyepoint Pharmaceuticals (Duravyu Phase 3 data expected Aug 2026), Vaxcyte (PCV Phase 3 OPUS-1 data in Q4 2026), Erasca (raised about $632.5M in an offering), and Arcutis (Zoryve guidance $480M-$495M for 2026).
5 min readEncompass Health (NYSE:EHC) discussed Q2 updates on an earnings call. It expects Medicare pricing impact of about 2.3% in Q4 and 2026 salary/wage growth of 3.5% to 4.0%. It cut the 2026 net provider-tax benefit to about $10M from ~$21M. The company opened new beds, raised its dividend to $0.21, repurchased shares, and issued $500M notes, with net leverage at 1.9x.
6 min readEncompass Health (EHC) reported Q2 2026 net operating revenue of $1,597.4 million and net income of $153.9 million, with higher EPS year over year. The company raised full-year 2026 revenue guidance and completed a major share repurchase program, retiring nearly one-tenth of shares, and increased shareholder returns. The article also cites higher debt after 2034 notes.
4 min read
